Transdermal hormone therapy: Gels and patches

Climacteric

Volumn 7, Issue 4, 2004, Pages 347-356

  Samsioe, G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Gels; Hormone therapy; Menopause; Patches; Transdermal

Indexed keywords

CHLORMADINONE ACETATE; CONJUGATED ESTROGEN; DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN DERIVATIVE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; VERALIPRIDE;

AREA UNDER THE CURVE; BLEEDING TENDENCY; BLISTER; BONE DENSITY; BONE MINERAL; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; BURNING SENSATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; ECZEMA; EDEMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ERYTHEMA; GALLSTONE FORMATION; GEL; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; METRORRHAGIA; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SKIN MANIFESTATION; SPOTTING; TABLET FORMULATION; TRANSDERMAL PATCH; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; CLIMACTERIC; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GELS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; SKIN ABSORPTION; UTERINE HEMORRHAGE;

EID: 11144343202     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130400012239     Document Type: Review

References (65)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women - principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
2. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002;288:49-57
3. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-22
4. Uhler ML, Marks JW, Judd HL. Estrogen replacement therapy and gallbladder disease in postmenopausal women. Menopause 2000;7:162-7
5. Samsioe G. The role of ERT/HRT. Best Pract Res Clin Obstet Gynaecol 2001;16:371-81
6. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000;102:2687-93
7. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol. Arzneim Forsch/Drug Res 1996;46:766-73
8. Järvinen A, Nykänen S, Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 1999;32:103-13
9. Paoletti AM, Pilia I, Nannipieri F, Bigini C, Melis GB. Comparison of pharmacokinetic profiles of a 17β-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state. Maturitas 2001;40:203-9
10. Järvinen A, Bäckström A-C, Elfström C, Viitanen A. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch. Maturitas 2001;38:189-96
11. Harrison LI, Harari D. An evaluation of bioequivalence of two 7-day 17β-estradiol transdermal delivery systems by anatomical site. J Clin Pharmacol 2002;42:1134-41
12. Järvinen A, Granander M, Nykänen S, Laine T, Geurts P, Viitanen A. Steady-state pharmacokinetics of oestradiol in postmenopausal women: effects of application area and washing. Br J Obstet Gynaecol 1997;104(Suppl 16):14-8
13. Buch A, Shen L, Kelly S, et al. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara. Menopause 1998;5:107-12
14. Bowen AJ, John VA, Ramirez ME, Good WR. Bioavailability of oestradiol from the Alora™ (0.1 mg/day) oestradiol matrix transdermal delivery system compared with Estraderm® (0.1 mg/day). J Obstet Gynaecol 1998;18:575-80
15. Reginster JY, Donazzolo Y, Brion N, Lins R. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches. Climacteric 2000;3:168-75
16. Rohr UD, Nauert C, Stehle B. 17β-estradiol delivered by three different matrix patches 50 μg/day: a three way cross-over study in 21 postmenopausal women. Maturitas 1999;33: 45-8
17. Buch AB, Shen LZ, Kelly SC, et al. Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems. Climacteric 1999;2:248-53
18. Hartl W, Wilfert HC, Heinz R. Results of an observation study with Estrogel and Utrogestan in patients with climacteric symptoms. J Menopause 1999;4:21-6
19. Foidart J-M, Béliard A, Hedon B, et al. Impact of percutaneous oestradiol gels in postmenopausal hormone replacement therapy on clinical symptoms and endometrium. Br J Obstet Gynaecol 1997;104:305-10
20. Hirvonen E, Crona N, Wahlstrom T, Backstrom A-C. Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding. Climacteric 2000;3:262-70
21. Heikkinen JE, Karjalainen AH, Backstrom A-C, Salinto M, Kesäniemi YA. Percutaneous and oral HRT alleviate climacteric symptoms equally well. Acta Obstet Gynecol Scand 1997; 76(Suppl):63
22. Hirvonen E, Lamberg-Allardt C, Lankinen KS, Geurts P, Wilén-Rosenqvist G. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Br J Obstet Gynaecol 1997;104(Suppl 16):19-25
23. DuPont A, Dupont P, Cusan L, et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991;13:297-311
24. Hirvonen E, Cacciatore B, Wahlström T, Rita H, Wilén- Rosenqvist G. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Br J Obstet Gynaecol 1997;104(Suppl 16):26-31
25. Notelovitz M. Clinical experience with a 7-day estrogen patch: principles and practice. Gynecol Endocrinol 1998;12:249-58
26. Elia D, Tamborini A, Leocmach Y, Chadha-Boreham H. Efficacy and tolerability of a low-dose of Oesclim® (25 μg daily) in the management of symptomatic menopausal women: a French open-label study. Curr Med Res Opin 2000;16:94-106
27. Pornel B, Genazzani AR, Costes D, Dain MP, Lelann L, Vandepol C. Efficacy and tolerability of Menorest® 50 compared with Estraderm® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter parallel group study. Maturitas 1995;22:207-18
28. Wren B. Menorest®: a clinical overview. Int J Gynecol Obstet 1996;52(Suppl 1):S27-9
29. Munoz A. Oesclim®: an advanced delivery system for HRT. Maturitas 1999;33:S39-47
30. Pornel B. Efficacy and safety of Menorest® in two positive-controlled studies. Eur J Obstet Gynecol 1996;64(Suppl 1):S35-7
31. Taurelle R, L'Hermite M, Haenggi W, Lauritzen C, Studd JW. The long-term tolerability and efficacy of Oesclim®: results of a 1-year study. Maturitas 1999;33:S73-81
32. Van Leusden HAIM, Albertyn G, Verlaine C, Van Ruymbeke J. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms. Int J Fertil 1993;38:210-8
33. Evans SF, Davie MWJ. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all postmenopausal ages. Clin Endocrinol 1996;44:79-84
34. Valimaki MJ, Laitinen KA, Tahtela RK, Hirvonen EJ, Risteli JP. The effects of transdermal estrogen therapy on bone mass and turnover in early postmenopausal smokers: a prospective, controlled study. Am J Obstet Gynecol 2003;189:1213-20
35. Jensen J, Christiansen C. Effects of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy. Am J Obstet Gynecol 1988;159:820-5
36. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
37. Scarabin PY, Oger E, Plu-Bureau G, EStrogen and ThromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32
38. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002;106:1771-6
39. Sendag F, Karadadas N, Ozsener S, Bilgin O. Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women. Arch Gynecol Obstet 2002;266:38-43
40. Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 1993;17:191-6
41. Karjalainen A, Heikkinen J, Savolainen MJ, Bäckström A-C, Salinto M, Kesäniemi YA. Metabolic changes induced by peroral oestrogen and transdermal oestradiol gel therapy. Br J Obstet Gynaecol 1997;104(Suppl 16):38-43
42. Kroon U-B, Tengborn L, Rita H, Bäckström A-C. The effects of transdermal oestradiol and oral progestogens on haemostasis variables. Br J Obstet Gynaecol 1997;104(Suppl 16):32-7
43. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003;41:1358-63
44. O'Sullivan AJ, Ho KKY. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995;80:1783-8
45. Karjalainen A, Paassilta M, Heikkinen A-C, Bäckström A-C, Savolainen M, Kesäniemi YA. Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism. Clin Endocrinol 2001;54:165-73
46. Shakir YA, Samsioe G, Nerbrand C, Lidfeldt J. Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women's Health in the Lund Area study. Menopause 2004;11:549-55
47. Brackman F. Oesclim®: summary of tolerability and safety. Maturitas 1999;33:S83-8
48. Whitehead MI, Fraser D, Schenkel L, Crook D, Stevenson JC. Transdermal administration of oestrogen/progestogen hormone replacement therapy. Lancet 1990;335:310-2
49. Li C, Samsioe G, Wilawan K, et al. Effects of norethisterone addition to estradiol in long-term HRT. Maturitas 2000;36:139-52
50. Mattsson LA, Bohnet HG, Gredmark T, Torhorst J, Horning F, Huls G. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. Obstet Gynecol 1999;94:61-5
51. Guichard J-P, Sauron R, Jones AB. Comparison of the pharmacokinetics of 17β-estradiol after a single 4-day application of Oesclim®50, Oesclim®100 and Vivelle®0.05 (Menorest® 50) transdermal delivery systems. J Clin Pharmacol 1999;39:811-6
52. Andersson TLG, Stehle B, Davidsson B, Hoglund P. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest® and Climara®. Maturitas 2000;34:57-64
53. Erianne JA, Winter L Jr. Comparison of the local tolerability and adhesion of a new matrix system (Menorest®) for estradiol delivery with an established transdermal membrane system (Estraderm TTS®). Maturitas 1997;26:95-101
54. Rozenbaum H, Birkhäuser M, De Nooyer C, et al. Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). II. Local skin tolerability. Maturitas 1996;25:175-85
55. Baz G, Quirce S, Montoya L, Alonso MD, Sánchez-Cano EAyM. Contact dermatitis due to transcutaneous estrogen administration. Rev Esp Alergol Immunol Clin 1998;13:28-31
56. El Sayed F, Bayle-Lebey P, Marguery MC, Bazex J. Sensibilisation systémique au 17β-oestradiol induite par la voie transcutanée. Ann Dermatol Venereol 1996;123:26-8
57. Frenkel Y, Kopernik G, Lazer S, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6
58. McCarthy TG, Dramusic V, Ratnam SS, Chang LM. Use of 50 μg Estraderm patches in a humid tropical climate. In Proceedings of the 5th International Congress of the Menopause. Carnforth, UK: Parthenon Publishing, 1987:122
59. Travassos de Figueiredo A, Amelia Sobreira GM, Clapauch R. Comparison of gel and patch estradiol replacement in Brazil, a tropical country. Maturitas 2000;36:69-74
60. Sentrakul P, Chompootaweep S, Sintupak S, Tasanapradit P, Tunsaringkarn K, Dusitsin N. Adverse skin reactions to transdermal oestradiol in tropical climates. A comparative study of skin tolerance after using oestradiol patch and gel in Thai postmenopausal women. Maturitas 1991;13:151-4
61. Hope S, Rees MCP. Why do British women start and stop hormone replacement therapy? J Br Menopause Soc 1995;1:26-7
62. Limouzin-Lamothe M-A, Mairon N, Joyce CRB, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170:618-24
63. Nathorst-Böös, Wiklund I, Mattsson L-Å, Sandin K, von Schoultz B. Is sexual life influenced by transdermal estrogen therapy? Acta Obstet Gynecol Scand 1993;72:656-60
64. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic center. Maturitas 1995;20:91-9
65. Gelas B, Thébault J, Roux I, Herbrecht F, Zartarian M. Comparative assessment of a new estradiol gel TX 11323 (A) and a transdermal therapeutic matrix system. Contracept Fertil Sex 1997;25:470-4